Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study

Objective To investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted Management in Early Rheumatoid Arthritis trial in early rheumatoid arthritis and evaluate the predictive value of an early response to treatment. Meth...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 70; no. 6; pp. 1099 - 1103
Main Authors Bakker, M F, Jacobs, J W G, Welsing, P M J, Vreugdenhil, S A, van Booma-Frankfort, C, Linn-Rasker, S P, Ton, E, Lafeber, F P J G, Bijlsma, J W J
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2011
BMJ Publishing Group
BMJ Publishing Group LTD
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objective To investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted Management in Early Rheumatoid Arthritis trial in early rheumatoid arthritis and evaluate the predictive value of an early response to treatment. Methods Clinical and radiographic 5-year outcome was compared between initial strategies. Patients were classified according to the EULAR response criteria. The prognostic value of early response to treatment in addition to established predictors was analysed by multiple linear regression analyses. Results 5 years of data were available for 205 of 299 patients, with no indication for selective drop-out. At 5 years there was no longer any significant difference for clinical and radiographic outcomes between treatment strategies applied during the first 2 years. Good-responders had a mean disease activity score of 2.39 (1.2) and median yearly radiographic progression rate of 0.6 (0.0 to 2.2) at 5 years; significantly lower (both p<0.02) when compared to moderate- and non-responders. Multiple regression analysis showed that early response to treatment is an independent predictor of 5-year outcome, irrespective of treatment strategy. Conclusions The difference in disease activity between treatment strategies disappeared over the years. Good-response to treatment independently predicts significantly better 5-year clinical and radiographic outcome. The TC principle probably should be continued in the long-term.
AbstractList Objective To investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted Management in Early Rheumatoid Arthritis trial in early rheumatoid arthritis and evaluate the predictive value of an early response to treatment. Methods Clinical and radiographic 5-year outcome was compared between initial strategies. Patients were classified according to the EULAR response criteria. The prognostic value of early response to treatment in addition to established predictors was analysed by multiple linear regression analyses. Results 5 years of data were available for 205 of 299 patients, with no indication for selective drop-out. At 5 years there was no longer any significant difference for clinical and radiographic outcomes between treatment strategies applied during the first 2 years. Good-responders had a mean disease activity score of 2.39 (1.2) and median yearly radiographic progression rate of 0.6 (0.0 to 2.2) at 5 years; significantly lower (both p<0.02) when compared to moderate- and non-responders. Multiple regression analysis showed that early response to treatment is an independent predictor of 5-year outcome, irrespective of treatment strategy. Conclusions The difference in disease activity between treatment strategies disappeared over the years. Good-response to treatment independently predicts significantly better 5-year clinical and radiographic outcome. The TC principle probably should be continued in the long-term.
Objective To investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted Management in Early Rheumatoid Arthritis trial in early rheumatoid arthritis and evaluate the predictive value of an early response to treatment. Methods Clinical and radiographic 5-year outcome was compared between initial strategies. Patients were classified according to the EULAR response criteria. The prognostic value of early response to treatment in addition to established predictors was analysed by multiple linear regression analyses. Results 5 years of data were available for 205 of 299 patients, with no indication for selective drop-out. At 5 years there was no longer any significant difference for clinical and radiographic outcomes between treatment strategies applied during the first 2 years. Good-responders had a mean disease activity score of 2.39 (1.2) and median yearly radiographic progression rate of 0.6 (0.0 to 2.2) at 5 years; significantly lower (both p<0.02) when compared to moderate- and non-responders. Multiple regression analysis showed that early response to treatment is an independent predictor of 5-year outcome, irrespective of treatment strategy. Conclusions The difference in disease activity between treatment strategies disappeared over the years. Good-response to treatment independently predicts significantly better 5-year clinical and radiographic outcome. The TC principle probably should be continued in the long-term.
OBJECTIVETo investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted Management in Early Rheumatoid Arthritis trial in early rheumatoid arthritis and evaluate the predictive value of an early response to treatment.METHODSClinical and radiographic 5-year outcome was compared between initial strategies. Patients were classified according to the EULAR response criteria. The prognostic value of early response to treatment in addition to established predictors was analysed by multiple linear regression analyses.RESULTS5 years of data were available for 205 of 299 patients, with no indication for selective drop-out. At 5 years there was no longer any significant difference for clinical and radiographic outcomes between treatment strategies applied during the first 2 years. Good-responders had a mean disease activity score of 2.39 (1.2) and median yearly radiographic progression rate of 0.6 (0.0 to 2.2) at 5 years; significantly lower (both p<0.02) when compared to moderate- and non-responders. Multiple regression analysis showed that early response to treatment is an independent predictor of 5-year outcome, irrespective of treatment strategy.CONCLUSIONSThe difference in disease activity between treatment strategies disappeared over the years. Good-response to treatment independently predicts significantly better 5-year clinical and radiographic outcome. The TC principle probably should be continued in the long-term.
To investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted Management in Early Rheumatoid Arthritis trial in early rheumatoid arthritis and evaluate the predictive value of an early response to treatment. Clinical and radiographic 5-year outcome was compared between initial strategies. Patients were classified according to the EULAR response criteria. The prognostic value of early response to treatment in addition to established predictors was analysed by multiple linear regression analyses. 5 years of data were available for 205 of 299 patients, with no indication for selective drop-out. At 5 years there was no longer any significant difference for clinical and radiographic outcomes between treatment strategies applied during the first 2 years. Good-responders had a mean disease activity score of 2.39 (1.2) and median yearly radiographic progression rate of 0.6 (0.0 to 2.2) at 5 years; significantly lower (both p<0.02) when compared to moderate- and non-responders. Multiple regression analysis showed that early response to treatment is an independent predictor of 5-year outcome, irrespective of treatment strategy. The difference in disease activity between treatment strategies disappeared over the years. Good-response to treatment independently predicts significantly better 5-year clinical and radiographic outcome. The TC principle probably should be continued in the long-term.
Author Linn-Rasker, S P
Bijlsma, J W J
Jacobs, J W G
van Booma-Frankfort, C
Welsing, P M J
Bakker, M F
Lafeber, F P J G
Ton, E
Vreugdenhil, S A
Author_xml – sequence: 1
  givenname: M F
  surname: Bakker
  fullname: Bakker, M F
  email: m.f.bakker-4@umcutrecht.nl
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
– sequence: 2
  givenname: J W G
  surname: Jacobs
  fullname: Jacobs, J W G
  email: m.f.bakker-4@umcutrecht.nl
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
– sequence: 3
  givenname: P M J
  surname: Welsing
  fullname: Welsing, P M J
  email: m.f.bakker-4@umcutrecht.nl
  organization: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
– sequence: 4
  givenname: S A
  surname: Vreugdenhil
  fullname: Vreugdenhil, S A
  email: m.f.bakker-4@umcutrecht.nl
  organization: Department of Rheumatology, St Antonius Hospital, Nieuwegein, The Netherlands
– sequence: 5
  givenname: C
  surname: van Booma-Frankfort
  fullname: van Booma-Frankfort, C
  email: m.f.bakker-4@umcutrecht.nl
  organization: Department of Rheumatology, Diakonessenhuis, Utrecht, The Netherlands
– sequence: 6
  givenname: S P
  surname: Linn-Rasker
  fullname: Linn-Rasker, S P
  email: m.f.bakker-4@umcutrecht.nl
  organization: Department of Rheumatology, Meander Medical Center, Amersfoort, The Netherlands
– sequence: 7
  givenname: E
  surname: Ton
  fullname: Ton, E
  email: m.f.bakker-4@umcutrecht.nl
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
– sequence: 8
  givenname: F P J G
  surname: Lafeber
  fullname: Lafeber, F P J G
  email: m.f.bakker-4@umcutrecht.nl
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
– sequence: 9
  givenname: J W J
  surname: Bijlsma
  fullname: Bijlsma, J W J
  email: m.f.bakker-4@umcutrecht.nl
  organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24167195$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21406458$$D View this record in MEDLINE/PubMed
BookMark eNqF0VFr1TAUB_AgE3c3ffZNAiKC0C1p0qTd2-Vy3WRTQabsLaTpKfbaJjVJ0fvtTendBnvxKZzkl8Ph_E_QkXUWEHpNyRmlTJxr35zlZK6YrDh7hlaUizLLiSBHaEUIYRmvhDxGJyHsUklKWr5AxznlRPCiXKG41b7fY9N3tjO6xx7C6GwAHB2OHnQcwEY8emg6EwMusj1oj90UjRsAdxZ_W-NRxy6pcIFb1_fuTzaNc5-pTx9a7wYcfwLerD9vkw1xavYv0fNW9wFeHc5T9P3j9nZzld18vfy0Wd9kNc9lzCoheG2YEVQX3ACpuClMZVrJCtqm21w0UGmhC1MyQ2sGwKUo80ZCSWvOgJ2i90vf0bvfE4Sohi4Y6HttwU1BlZJRWlHOk3z7RO7c5G0aTlEpSyLmjSZ1vijjXQgeWjX6btB-ryhRcx4q5aHmPNSSR_rx5tB3qgdoHvx9AAm8OwAd0v5br63pwqPjVEhaFclli-tChL8P79r_UkIyWagvPzbq7pIKcX19q-6S_7D4etj9d8p_PZGwlQ
CODEN ARDIAO
CitedBy_id crossref_primary_10_1016_j_berh_2011_10_006
crossref_primary_10_1016_j_rhum_2019_02_013
crossref_primary_10_1093_rheumatology_kez101
crossref_primary_10_1007_s15006_012_1299_1
crossref_primary_10_1016_j_berh_2013_10_002
crossref_primary_10_1136_annrheumdis_2015_208941
crossref_primary_10_2217_ijr_12_76
crossref_primary_10_1016_j_jbspin_2019_03_008
crossref_primary_10_1186_s13075_018_1514_2
crossref_primary_10_1007_s00393_012_1048_y
crossref_primary_10_1097_RHU_0b013e31826d6610
crossref_primary_10_1186_s12967_018_1387_9
crossref_primary_10_1016_j_berh_2014_07_001
crossref_primary_10_1002_acr_22426
crossref_primary_10_1002_msc_1681
crossref_primary_10_1007_s42399_021_00727_4
crossref_primary_10_1186_s13075_023_03038_2
crossref_primary_10_1136_rmdopen_2020_001208
crossref_primary_10_1016_j_rdc_2012_04_004
crossref_primary_10_3899_jrheum_120715
crossref_primary_10_1002_acr_22681
crossref_primary_10_1007_s10067_019_04600_7
crossref_primary_10_1093_rheumatology_kes083
crossref_primary_10_1586_14737159_2015_969244
crossref_primary_10_5114_reum_2018_74741
crossref_primary_10_1093_rheumatology_kes084
crossref_primary_10_1016_j_reuma_2017_07_004
crossref_primary_10_1093_rheumatology_kes087
crossref_primary_10_1186_ar3706
crossref_primary_10_1186_s13550_023_01064_4
crossref_primary_10_1136_bmjopen_2013_003083
crossref_primary_10_3310_hta21710
crossref_primary_10_1136_rmdopen_2015_000057
crossref_primary_10_1016_j_reumae_2018_10_008
crossref_primary_10_1007_s00393_012_1038_0
crossref_primary_10_1097_BOR_0b013e32835fd294
crossref_primary_10_1111_hir_12230
crossref_primary_10_1007_s10067_017_3962_5
crossref_primary_10_3310_pgfar09080
crossref_primary_10_4103_ejos_ejos_44_23
crossref_primary_10_2174_1874312901812010179
ContentType Journal Article
Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
2015 INIST-CNRS
Copyright: 2011 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Copyright_xml – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
– notice: 2015 INIST-CNRS
– notice: Copyright: 2011 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
CorporateAuthor Utrecht Arthritis Cohort Study Group
CorporateAuthor_xml – name: Utrecht Arthritis Cohort Study Group
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
88E
88I
8AF
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9-
K9.
LK8
M0R
M0S
M1P
M2P
M7P
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
DOI 10.1136/ard.2010.137943
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
BMJ Journals
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
Consumer Health Database
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Consumer Health Database
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
ProQuest Science Journals
ProQuest Biological Science Journals
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
ProQuest Central Student
CrossRef
MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 1103
ExternalDocumentID 4008525841
10_1136_ard_2010_137943
21406458
24167195
ark_67375_NVC_XG166KKT_X
ttp://ard.bmj.com/content/70/6/1099.full
Genre Randomized Controlled Trial
Journal Article
GroupedDBID ---
.55
.GJ
.VT
0R~
23M
2WC
39C
3O-
3V.
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOFX
ACPRK
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FRP
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IGG
IHR
INH
INR
IOF
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
R53
RHF
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
BSCLL
ITC
8RD
AAUGY
BHJZB
BJGMD
IQODW
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7XB
8FK
K9.
PQEST
PQUKI
PRINS
Q9U
7X8
ID FETCH-LOGICAL-b427t-9664bc3c61a54ce094c5c9cf7351fc6126de9a6a5c83c1b3ee47682d7e81b43e3
IEDL.DBID 7X7
ISSN 0003-4967
IngestDate Sat Aug 17 03:14:46 EDT 2024
Thu Oct 10 15:32:18 EDT 2024
Thu Sep 26 16:36:29 EDT 2024
Sat Sep 28 07:52:37 EDT 2024
Sun Oct 22 16:03:15 EDT 2023
Wed Oct 30 09:30:52 EDT 2024
Wed Aug 21 03:29:16 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Human
Immunopathology
Chronic
Prognosis
Treatment
Rheumatoid arthritis
Diseases of the osteoarticular system
Rheumatology
Autoimmune disease
Inflammatory joint disease
Predictive factor
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b427t-9664bc3c61a54ce094c5c9cf7351fc6126de9a6a5c83c1b3ee47682d7e81b43e3
Notes local:annrheumdis;70/6/1099
istex:B4788075055B0CA609A34C70CDA2B387D3D4BB73
href:annrheumdis-70-1099.pdf
ArticleID:annrheumdis137943
PMID:21406458
ark:/67375/NVC-XG166KKT-X
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
PMID 21406458
PQID 1778062060
PQPubID 2041045
PageCount 5
ParticipantIDs proquest_miscellaneous_873119144
proquest_journals_1778062060
crossref_primary_10_1136_ard_2010_137943
pubmed_primary_21406458
pascalfrancis_primary_24167195
istex_primary_ark_67375_NVC_XG166KKT_X
bmj_primary_10_1136_ard_2010_137943
PublicationCentury 2000
PublicationDate 2011-06-01
PublicationDateYYYYMMDD 2011-06-01
PublicationDate_xml – month: 06
  year: 2011
  text: 2011-06-01
  day: 01
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Annals of the rheumatic diseases
PublicationTitleAlternate Ann Rheum Dis
PublicationYear 2011
Publisher BMJ Publishing Group Ltd and European League Against Rheumatism
BMJ Publishing Group
BMJ Publishing Group LTD
Publisher_xml – name: BMJ Publishing Group Ltd and European League Against Rheumatism
– name: BMJ Publishing Group
– name: BMJ Publishing Group LTD
References Wessels, van der Kooij, le Cessie 2007; 56
Klarenbeek, Allaart, Kerstens 2009; 21
Smolen, Aletaha, Bijlsma 2010; 69
Goekoop-Ruiterman, de Vries-Bouwstra, Allaart 2005; 52
Aletaha, Funovits, Keystone 2007; 56
Prevoo, van 't Hof, Kuper 1995; 38
Smolen, Van Der Heijde, St Clair 2006; 54
van der Heijde, van Riel, Nuver-Zwart 1989; 1
Vázquez, Graell, Gratacós 2007; 25
Bakker, Jacobs, Welsing 2010; 69
Grigor, Capell, Stirling 2004; 364
van Gestel, Prevoo, van 't Hof 1996; 39
Nell, Machold, Eberl 2004; 43
Verstappen, Jacobs, van der Veen 2007; 66
Machold, Stamm, Nell 2007; 46
Puolakka, Kautiainen, Möttönen 2005; 52
Rantalaiho, Korpela, Hannonen 2009; 60
Möttönen, Hannonen, Leirisalo-Repo 1999; 353
References_xml – volume: 69
  start-page: 631
  year: 2010
  article-title: Treating rheumatoid arthritis to target: recommendations of an international task force.
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Bijlsma
– volume: 66
  start-page: 1443
  year: 2007
  article-title: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).
  publication-title: Ann Rheum Dis
  contributor:
    fullname: van der Veen
– volume: 52
  start-page: 36
  year: 2005
  article-title: Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
  publication-title: Arthritis Rheum
  contributor:
    fullname: Möttönen
– volume: 56
  start-page: 3226
  year: 2007
  article-title: Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.
  publication-title: Arthritis Rheum
  contributor:
    fullname: Keystone
– volume: 69
  start-page: 1849
  year: 2010
  article-title: Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study.
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Welsing
– volume: 54
  start-page: 702
  year: 2006
  article-title: Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
  publication-title: Arthritis Rheum
  contributor:
    fullname: St Clair
– volume: 60
  start-page: 1222
  year: 2009
  article-title: The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
  publication-title: Arthritis Rheum
  contributor:
    fullname: Hannonen
– volume: 353
  start-page: 1568
  year: 1999
  article-title: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
  publication-title: Lancet
  contributor:
    fullname: Leirisalo-Repo
– volume: 39
  start-page: 34
  year: 1996
  article-title: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.
  publication-title: Arthritis Rheum
  contributor:
    fullname: van 't Hof
– volume: 56
  start-page: 1765
  year: 2007
  article-title: A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.
  publication-title: Arthritis Rheum
  contributor:
    fullname: le Cessie
– volume: 1
  start-page: 1036
  year: 1989
  article-title: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.
  publication-title: Lancet
  contributor:
    fullname: Nuver-Zwart
– volume: 46
  start-page: 342
  year: 2007
  article-title: Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease.
  publication-title: Rheumatology (Oxford)
  contributor:
    fullname: Nell
– volume: 38
  start-page: 44
  year: 1995
  article-title: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.
  publication-title: Arthritis Rheum
  contributor:
    fullname: Kuper
– volume: 25
  start-page: 231
  year: 2007
  article-title: Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.
  publication-title: Clin Exp Rheumatol
  contributor:
    fullname: Gratacós
– volume: 52
  start-page: 3381
  year: 2005
  article-title: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
  publication-title: Arthritis Rheum
  contributor:
    fullname: Allaart
– volume: 364
  start-page: 263
  year: 2004
  article-title: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
  publication-title: Lancet
  contributor:
    fullname: Stirling
– volume: 21
  start-page: 291
  year: 2009
  article-title: The BeSt story: on strategy trials in rheumatoid arthritis.
  publication-title: Curr Opin Rheumatol
  contributor:
    fullname: Kerstens
– volume: 43
  start-page: 906
  year: 2004
  article-title: Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.
  publication-title: Rheumatology (Oxford)
  contributor:
    fullname: Eberl
SSID ssj0000818
Score 2.2544608
Snippet Objective To investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted...
To investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted Management in Early...
Objective To investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted...
OBJECTIVETo investigate the long-term effects of the tight control (TC) and conventional (CT) methotrexate-based strategies of the Computer Assisted Management...
SourceID proquest
crossref
pubmed
pascalfrancis
istex
bmj
SourceType Aggregation Database
Index Database
Publisher
StartPage 1099
SubjectTerms Adult
Aged
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - diagnostic imaging
Arthritis, Rheumatoid - drug therapy
Biological and medical sciences
Biomarkers - blood
Blood Sedimentation
C-Reactive Protein - metabolism
Cameras
Clinical medicine
Disease Progression
Diseases of the osteoarticular system
Drug Therapy, Computer-Assisted
Epidemiologic Methods
Female
Humans
Inflammatory joint diseases
Male
Medical sciences
Methotrexate - administration & dosage
Methotrexate - therapeutic use
Middle Aged
Patients
Radiography
Rheumatoid arthritis
Studies
Treatment Outcome
Title Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study
URI http://dx.doi.org/10.1136/ard.2010.137943
https://api.istex.fr/ark:/67375/NVC-XG166KKT-X/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/21406458
https://www.proquest.com/docview/1778062060
https://search.proquest.com/docview/873119144
Volume 70
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagKyEuiDeBsrIEQlyiruNXwgUtq5aKqitUtSg3y3ZsiVeybBIB_55x4uyqB-CaxD7MN7G_GY-_QehlRan11mSpYHqRMlbZtDBaptIC15YeSIQJqYHztTi9Yh9KXsaEWxvLKqc1cVioq8aGHPkRkTJfiGwhFm83P9LQNSqcrsYWGjfRjMCr4NWylPuVOCf51DGPFUJGaR9CxRGYf6zrIjRIpMHOYr5_ubY3zYKZf4VaSd2CufzY5-LvRHTYkE7uojuRSeLlCP09dMPV99Gt83hW_gB1g3Yxnq4-4u1YDetw1-BdeTnebMOArsU8_Q1Oj5u-A3s4_LnGF0scVVfbN9iDvzQ_034T5um_wYBwMQUDfcSroK2wxINQ7UN0dXJ8uTpNY4-F1LBMdkGckxlLrSCaM-sg2LPcFtZLyomHp5moXKGF5janlhjqHIMAJaukA77LqKOP0EHd1O4JwtxDrJjlRmrpWOUyE0IpbyjT3ruK6wS9ABurzaiioYbogwoFSKiAhBqRSNDrCYP_f_pqwGj3nd5-DXVqkqv1p5Uq3xMhzs4uVZmg-TUQdwOAvghJCp6gwwlVFf_hVu09LkF49xr-vnCkomvX9K3KJR0U8liCHo_OsJ8bQlfBeP7033M_Q7fHNHVI7Byig27bu-fAczozH5x5jmbvjtcfL_4A12v6Vw
link.rule.ids 315,783,787,12069,21401,27937,27938,31732,31733,33757,33758,43323,43818,74080,74637
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lj9MwELZgVwIuiOcSWBZLIMQl2jp-JVxQVbEUuu0BdVFulu3YEo9Nuk0i4N8zzqPVHoBrEvsw38T-Zjz-BqFXBaXWW5PEgulJzFhh48xoGUsLXFt6IBEmpAaWKzG_YJ9yng8Jt3ooqxzXxG6hLiobcuSnRMp0IpKJmLzbXMWha1Q4XR1aaNxEh0GHK_i5zOV-JU5JOnbMY5mQg7QPoeIUzN_XdREaJNJgZzGX367tTYfBzL9CraSuwVy-73PxdyLabUhn99DdgUniaQ_9fXTDlQ_QreVwVv4QNZ12MR6vPuJtXw3rcFPhXXk53mzDgKbGPP4NTo-rtgF7OPy1xJ-neFBdrd9iD_5S_YzbTZin_QEDwsUUDPQRz4K2whR3QrWP0MXZ-_VsHg89FmLDEtkEcU5mLLWCaM6sg2DPcptZLyknHp4monCZFprblFpiqHMMApSkkA74LqOOPkYHZVW6JwhzD7FikhqppWOFS0wIpbyhTHvvCq4j9BJsrDa9iobqog8qFCChAhKqRyJCb0YM_v_p6w6j3Xd6-z3UqUmuVl9mKv9AhFgs1iqP0Mk1EHcDgL4ISTIeoeMRVTX8w7Xae1yE8O41_H3hSEWXrmprlUraKeSxCB31zrCfG0JXwXj69N9zv0C35-vluTr_uFo8Q3f6lHVI8hyjg2bbuufAeRpz0jn2H87a-6Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3Pb9MwFLZglSYuiN8ExrAEQlyiNvGvhAsqZWVQVk3ThnqzbMeWYCMpTSLgv-c5cVrtAFwT24f3Pdvfs5-_h9DLghDjjE5jTtUkprQwca6ViIUBri0ckAjtjwZOlvz4gn5asVXIf6pDWuWwJnYLdVEZf0Y-ToTIJjyd8MnYhbSI0_fzt-sfsa8g5W9aQzmNm2gkKCcQiI3eHS1Pz3brcpZkQ_08mnMRhH4SwscARp_llRAvmAb7jP7-7dpONfJG_-UzJ1UNxnN91Yu_09Jue5rfQbcDr8TT3hHuohu2vIf2T8LN-X3UdErGeHgIiTd9bqzFTYW3yeZ4vfEdmhqz-DdMAVy1DVjH4q8lPpvioMFav8EOvKf6GbdrP057BR38MxUMZBLPvNLCFHeytQ_QxfzofHYch4oLsaapaLxUJ9WGGJ4oRo2F0M8wkxsnCEscfE15YXPFFTMZMYkm1lIIV9JCWGC_lFjyEO2VVWkfI8wcRI5ppoUSlhY21T6wcppQ5ZwtmIrQC7CxXPeaGrKLRQiXgIT0SMgeiQi9HjD4f9NXHUbbdmpz6bPWBJPLLzO5-pBwvlicy1WEDq-BuO0AZIaLJGcROhhQlWFG13LnfxHC298wF_0Fiypt1dYyE6TTy6MRetQ7w25sCGQ5ZdmTf4_9HO2DV8vPH5eLp-hWf37tT3wO0F6zae0zIECNPgye_Qc2fgFW
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+clinical+response+to+treatment+predicts+5-year+outcome+in+RA+patients%3A+follow-up+results+from+the+CAMERA+study&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Bakker%2C+M+F&rft.au=Jacobs%2C+J+W+G&rft.au=Welsing%2C+P+M+J&rft.au=Vreugdenhil%2C+S+A&rft.date=2011-06-01&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=70&rft.issue=6&rft.spage=1099&rft_id=info:doi/10.1136%2Fard.2010.137943&rft.externalDBID=ttp%3A%2F%2Fard.bmj.com%2Fcontent%2F70%2F6%2F1099.full.pdf&rft.externalDocID=ttp%3A%2F%2Fard.bmj.com%2Fcontent%2F70%2F6%2F1099.full
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon